+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Immunotherapy Drug Discovery Outsourcing - Global Market Trajectory & Analytics

  • ID: 5303355
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Aquila Biomedical
  • Celentyx Ltd.
  • Crown Bioscience Inc.
  • Explicit Immuno-Oncology
  • HD Biosciences Co. Ltd.
  • Personalis, Inc.
Global Cancer Immunotherapy Drug Discovery Outsourcing Market to Reach $2 Billion by 2027

Amid the COVID-19 crisis, the global market for Cancer Immunotherapy Drug Discovery Outsourcing estimated at US$879.3 Million in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 12.2% over the analysis period 2020-2027. Monoclonal Antibodies, one of the segments analyzed in the report, is projected to record a 11.7% CAGR and reach US$746.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immunomodulators segment is readjusted to a revised 13.1% CAGR for the next 7-year period.



The U.S. Market is Estimated at $237.4 Million, While China is Forecast to Grow at 16% CAGR

The Cancer Immunotherapy Drug Discovery Outsourcing market in the U.S. is estimated at US$237.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$427.8 Million by the year 2027 trailing a CAGR of 15.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.6% and 10.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Oncolytic Viral Therapies & Cancer Vaccines Segment to Record 12.3% CAGR

In the global Oncolytic Viral Therapies & Cancer Vaccines segment, USA, Canada, Japan, China and Europe will drive the 11.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$138.3 Million in the year 2020 will reach a projected size of US$296 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$290.8 Million by the year 2027, while Latin America will expand at a 13.8% CAGR through the analysis period.

Select Competitors (Total 34 Featured):
  • Aquila Biomedical
  • BPS Biosciences Inc.
  • Celentyx Ltd.
  • Covance, Inc.
  • Crown Bioscience Inc.
  • DiscoverX Corporation
  • Explicit Immuno-Oncology
  • Explicyte
  • Gen script Biotech Corporation
  • HD Biosciences Co. Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Molecular Imaging Inc. (MI Bioresearch Inc.)
  • Personalis, Inc.
  • Promega Corporation
  • STC Biologics
Frequently Asked Questions about the Global Market for Cancer Immunotherapy Drug Discovery Outsourcing

What is the estimated value of the Global Market for Cancer Immunotherapy Drug Discovery Outsourcing?

The Global Market for Cancer Immunotherapy Drug Discovery Outsourcing was estimated to be valued at $879.3 Million in 2020.

What is the growth rate of the Global Market for Cancer Immunotherapy Drug Discovery Outsourcing?

The growth rate of the Global Market for Cancer Immunotherapy Drug Discovery Outsourcing is 12.5%, with an estimated value of $2000.0 Million by 2027.

What is the forecasted size of the Global Market for Cancer Immunotherapy Drug Discovery Outsourcing?

The Global Market for Cancer Immunotherapy Drug Discovery Outsourcing is estimated to be worth $2000.0 Million by 2027.

Who are the key companies in the Global Market for Cancer Immunotherapy Drug Discovery Outsourcing?

Key companies in the Global Market for Cancer Immunotherapy Drug Discovery Outsourcing include Aquila Biomedical, BPS Biosciences Inc., Celentyx Ltd., Covance, Inc., Crown Bioscience Inc., DiscoverX Corporation, Explicit Immuno, Oncology and Gen script Biotech Corporation.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aquila Biomedical
  • Celentyx Ltd.
  • Crown Bioscience Inc.
  • Explicit Immuno-Oncology
  • HD Biosciences Co. Ltd.
  • Personalis, Inc.

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • AUSTRALIA
  • INDIA
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA

IV. COMPETITION
  • Total Companies Profiled: 34
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Aquila Biomedical
  • BPS Biosciences Inc.
  • Celentyx Ltd.
  • Covance, Inc.
  • Crown Bioscience Inc.
  • DiscoverX Corporation
  • Explicit Immuno-Oncology
  • Explicyte
  • Gen script Biotech Corporation
  • HD Biosciences Co. Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Molecular Imaging Inc. (MI Bioresearch Inc.)
  • Personalis, Inc.
  • Promega Corporation
  • STC Biologics
Note: Product cover images may vary from those shown